Breaking News Instant updates and real-time market news.

MNTA

Momenta

$13.90

-0.25 (-1.77%)

, SHPG

Shire

$174.84

-0.39 (-0.22%)

08:11
11/29/16
11/29
08:11
11/29/16
08:11

Momenta announces M923 clinical study met primary endpoint

Momenta Pharmaceuticals (MNTA) announced that the confirmatory Phase 3 clinical study of M923, a biosimilar HUMIRA candidate developed in collaboration with Baxalta, now part of Shire (SHPG), in patients with moderate-to-severe chronic plaque psoriasis, met its primary endpoint. The proportion of subjects in the study who achieved the primary endpoint, at least 75% reduction in the Psoriasis Area and Severity Index following 16 weeks of treatment, was equivalent between M923 and HUMIRA. The estimated difference in responders was well within the pre-specified confidence interval, confirming equivalence. Equivalence was also achieved in all secondary efficacy endpoints, including the achievement of PASI-50, PASI-90, proportion achieving clear or near-clear skin, and change from baseline in absolute PASI score. Adverse events were comparable in terms of type, frequency, and severity, and were consistent with the published safety data for HUMIRA.

MNTA

Momenta

$13.90

-0.25 (-1.77%)

SHPG

Shire

$174.84

-0.39 (-0.22%)

  • 03

    Dec

MNTA Momenta
$13.90

-0.25 (-1.77%)

09/02/16
LEER
09/02/16
NO CHANGE
LEER
Outperform
Teva third Copaxone patent invalidated as expected, says Leerink
Leerink analyst Jason Gerberry says Teva (TEVA) suffered a largely expected loss in its Copaxone 40mg patent battle, with the Patent Trial and Appeal Board, or PTAB, ruling a third patent invalid. The analyst believes the company will likely appeal the loss, along with PTAB rulings rendered last week that other Copaxone patents were invalid. Gerberry sees the bull case scenario of Teva securing patent exclusivity of the Copaxone 40mg as unlikely and says a settlement with Momenta (MNTA) and Novartis (NVS) is the most logical course of action to mitigate 2017-2018E EPS risk. He reiterates an Outperform rating on Teva's shares.
09/07/16
MAXM
09/07/16
DOWNGRADE
MAXM
Sell
Momenta downgraded to Sell from Hold at Maxim
10/11/16
LEHM
10/11/16
UPGRADE
Target $19
LEHM
Overweight
Momenta upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Douglas Tsao upgraded Momenta Pharmaceuticals to Overweight after attending the consolidated Copaxone 40mg trial. The analyst sees low risk of Momenta being blocked from the 40mg opportunity past 2018 and views the stock's risk/reward as "compelling" at current levels. Tsao believes there is a "good likelihood" that Sandoz, Momenta's partner, launches Copaxone 40mg at-risk as soon as February 2017 upon FDA approval when the 30-month stay expires. The analyst raised his price target for Momenta shares to $19 from $13.
11/22/16
AGIS
11/22/16
INITIATION
Target $15
AGIS
Hold
Momenta initiated with a Hold at Aegis
Aegis analyst Difei Yang iniatied Momenta with a Hold and a $15 price target.
SHPG Shire
$174.84

-0.39 (-0.22%)

11/01/16
BTIG
11/01/16
NO CHANGE
Target $242
BTIG
Buy
Shire's recent weakness overdone, says BTIG
BTIG analyst Timothy Chiang believes the recent selloff in Shire is overdone and that weakness in the Hematology segment was impacted by the timing of large orders. The analyst maintains his Buy rating and $242 price target on Shire shares.
11/02/16
LEER
11/02/16
NO CHANGE
Target $198
LEER
Outperform
Shire price target lowered to $198 from $234 at Leerink
Following a modest Q3 miss, Leerink analyst Jason Gerberry lowered his price target for Shire to $198 from $234 to reflect a more conservative outlook on key franchises due to out-year competitive pressures. The analyst reiterates an Outperform rating on the stock as he believes concerns around pricing look overdone and shares are attractively valued.
11/09/16
SBSH
11/09/16
NO CHANGE
SBSH
Citi sees Healthcare 'relief rally' after Trump win
Citi analyst Andrew Baum expects a "'relief rally" to drive near-term sector outperformance for names in the Healthcare space given the "inability of the Democrats to attain the Presidency, the House or Congress." Longer term, however, the analyst still sees "significant continued legislative risk" for pharma reimbursement. Baum prefers GlaxoSmithKline (GSK), AstraZeneca (AZN), Shire (SHPG) and Roche (RHHBY) among European majors and Bristol-Myers (BMY) and Eli Lilly (LLY) in the U.S.
11/14/16
JPMS
11/14/16
NO CHANGE
JPMS
JPMorgan says Merrimack could fit as target for Shire
JPMorgan analyst Anupam Rama believes Merrimack Pharmaceuticals (MACK) could fit as a potential target for Shire (SHPG). The $1B deal size would be manageable, Rama tells investors in a research note after Ben Harrington's Betaville blog, citing sources, reported Friday that Shire is among the companies participating in Merrimack's strategic review process. Assuming a 40% premium to the intraday Merrimack share price, the deal would be 1% accretive in 2019 and 2% accretive in 2020, Rama estimates.

TODAY'S FREE FLY STORIES

LIOX

Lionbridge

16:58
02/26/17
02/26
16:58
02/26/17
16:58
Conference/Events
Lionbridge to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMCSA

Comcast

$37.89

0.24 (0.64%)

, CMCSK

Comcast

16:54
02/26/17
02/26
16:54
02/26/17
16:54
Hot Stocks
Box Office Battle: Comedy horror 'Get Out' thrills in $31M opening »

Comcast's (CMCSA)…

CMCSA

Comcast

$37.89

0.24 (0.64%)

CMCSK

Comcast

TWX

Time Warner

$97.28

0.6225 (0.64%)

LGF.A

Lionsgate

$27.18

-0.08 (-0.29%)

LGF.B

Lionsgate

$25.16

-0.19 (-0.75%)

DIS

Disney

$110.32

0.59 (0.54%)

FOX

21st Century Fox

$30.23

0.23 (0.77%)

FOXA

21st Century Fox

$30.61

0.27 (0.89%)

VIA

Viacom

VIAB

Viacom

$43.89

0.03 (0.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

  • 06

    Mar

WAT

Waters

$156.40

1.51 (0.97%)

16:38
02/26/17
02/26
16:38
02/26/17
16:38
Conference/Events
Waters to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

  • 01

    Apr

CR

Crane

$73.21

1.18 (1.64%)

16:36
02/26/17
02/26
16:36
02/26/17
16:36
Conference/Events
Crane to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

DBOEY

Deutsche Boerse

$8.60

-0.045 (-0.52%)

16:34
02/26/17
02/26
16:34
02/26/17
16:34
Hot Stocks
LSE rejects European Commission merger demand, says unlikely to approve deal »

London Stock Exchange…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BCO

Brink's

$52.00

0.7 (1.36%)

16:33
02/26/17
02/26
16:33
02/26/17
16:33
Conference/Events
Brink's to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

XOM

Exxon Mobil

$81.08

-0.7 (-0.86%)

16:28
02/26/17
02/26
16:28
02/26/17
16:28
Conference/Events
Exxon Mobil to host analyst meeting with a conference call hook-up »

Analyst meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TXMD

TherapeuticsMD

$5.84

0.2 (3.55%)

16:22
02/26/17
02/26
16:22
02/26/17
16:22
Conference/Events
TherapeuticsMD to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

  • 21

    Mar

  • 07

    May

MYL

Mylan

$42.16

-0.17 (-0.40%)

16:19
02/26/17
02/26
16:19
02/26/17
16:19
Conference/Events
Mylan to host investor day with a conference call hook-up »

CEO Bresch holds an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

  • 01

    Mar

  • 28

    Mar

  • 03

    Sep

  • 09

    Oct

MCD

McDonald's

$128.65

0.38 (0.30%)

16:16
02/26/17
02/26
16:16
02/26/17
16:16
Conference/Events
McDonald's to host investor meeting »

Investor meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HSY

Hershey

$108.90

0.25 (0.23%)

16:13
02/26/17
02/26
16:13
02/26/17
16:13
Conference/Events
Hershey to hold a webcast »

Incoming CEO Michelle…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

SSNLF

Samsung

, FB

Facebook

$135.44

0.08 (0.06%)

16:10
02/26/17
02/26
16:10
02/26/17
16:10
Hot Stocks
Samsung introduces Gear VR with controller »

Samsung (SSNLF) announced…

SSNLF

Samsung

FB

Facebook

$135.44

0.08 (0.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 28

    Feb

  • 28

    Feb

  • 06

    Mar

  • 19

    Mar

  • 28

    Mar

SSNLF

Samsung

16:08
02/26/17
02/26
16:08
02/26/17
16:08
Hot Stocks
Samsung announces Galaxy Tab S3, Galaxy Book tablets »

Samsung announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 28

    Mar

SSNLF

Samsung

, HAR

Harman

$111.44

0.34 (0.31%)

16:06
02/26/17
02/26
16:06
02/26/17
16:06
Hot Stocks
Samsung, Harman announce audio collaboration for Galaxy devices »

Samsung (SSNLF) and…

SSNLF

Samsung

HAR

Harman

$111.44

0.34 (0.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 28

    Mar

EFX

Equifax

$129.38

0.16 (0.12%)

16:06
02/26/17
02/26
16:06
02/26/17
16:06
Conference/Events
Equifax management to meet with investors »

CFO Gamble to meet with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 01

    Mar

MRK

Merck

$66.16

0.31 (0.47%)

16:03
02/26/17
02/26
16:03
02/26/17
16:03
Hot Stocks
Merck says Phase 3 letermovir study meets primary efficacy goal »

Merck announced results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

  • 08

    Mar

  • 15

    Mar

  • 01

    Apr

  • 10

    May

  • 27

    May

  • 14

    Jun

EFX

Equifax

$129.38

0.16 (0.12%)

16:03
02/26/17
02/26
16:03
02/26/17
16:03
Conference/Events
Equifax management to meet with investors »

Chairman & CEO Smith,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

NOK

Nokia

$5.14

-0.01 (-0.19%)

15:58
02/26/17
02/26
15:58
02/26/17
15:58
Hot Stocks
Nokia announces expanded portfolio of digital health products, solutions »

Nokia announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 23

    May

TGT

Target

$66.51

1.53 (2.35%)

15:45
02/26/17
02/26
15:45
02/26/17
15:45
Conference/Events
Target to hold a financial community meeting »

Management holds 2017…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 28

    Feb

  • 19

    Mar

GPRO

GoPro

$9.43

-0.14 (-1.46%)

15:42
02/26/17
02/26
15:42
02/26/17
15:42
Hot Stocks
GoPro says 'Quik' app chosen by Huawei for latest devices »

GoPro announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

LGND

Ligand

$100.38

-2.46 (-2.39%)

15:40
02/26/17
02/26
15:40
02/26/17
15:40
Conference/Events
Ligand to host analyst day »

Analyst Day to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 02

    Mar

HURN

Huron

$44.30

-0.8 (-1.77%)

15:39
02/26/17
02/26
15:39
02/26/17
15:39
Conference/Events
Huron to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

ENS

EnerSys

$75.98

-0.77 (-1.00%)

15:36
02/26/17
02/26
15:36
02/26/17
15:36
Conference/Events
EnerSys to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

  • 17

    Mar

ERIC

Ericsson

$6.45

-0.08 (-1.23%)

15:36
02/26/17
02/26
15:36
02/26/17
15:36
Hot Stocks
Ericsson says selected by Batelco for mobile network enhancement »

Ericsson announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

  • 29

    Mar

QCOM

Qualcomm

$57.22

0.08 (0.14%)

15:33
02/26/17
02/26
15:33
02/26/17
15:33
Conference/Events
Qualcomm to hold an investor session at Mobile World Congress 2017 »

Management holds an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 13

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.